Kythera Biophrarma (KYTH) Tops Q1 EPS by 236c

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/15/2026

1. NVDA
2. CRWV
3. SPY
4. BAC
5. BLK
6. AA
7. RKLB
8. CAT
9. FMC
10. MRSH

Go back to Kythera Biophrarma (KYTH) Tops Q1 EPS by 236c

KYTHERA Biopharmaceuticals Releases First Quarter 2015 Operating Results and Progress Update

May 7, 2015 4:06 PM EDT

WESTLAKE VILLAGE, Calif., May 7, 2015 (GLOBE NEWSWIRE) -- KYTHERA Biopharmaceuticals, Inc. (Nasdaq: KYTH) today reported financial results for the first quarter of 2015, and provided an update on recent accomplishments.

KYTHERA recently achieved our most significant milestone to date, that of receiving FDA approval of KYBELLA, which is the first and only FDA approved injectable drug that contours and improves the appearance of submental fullness, said Keith Leonard, KYTHERAs President and CEO. This approval came after we received a unanimous (17-0) recommendation for approval for KYBELLA from the FDAs Dermatologic and Ophthalmic Drugs... More